Segment Information (Details) (USD $) In Thousands, unless otherwise specified	1 Months Ended	3 Months Ended								12 Months Ended
	Jun. 30, 2011 segment	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012 segment product	Dec. 31, 2011	Dec. 31, 2010
Segment Information
Number of operating segments	2									1
Number of commercial products										3
Revenues, cost of revenues and gross profit
Revenues										$ 906,123	$ 741,094	$ 591,702
Cost of revenues										119,297	88,904	67,674
Gross profit		202,766	212,949	192,199	178,912	168,983	178,344	162,384	142,479	786,826	652,190	524,028
Remodulin
Revenues, cost of revenues and gross profit
Revenues										457,969	430,132	403,598
Cost of revenues										57,618	52,329	35,115
Gross profit										400,351	377,803	368,483
Tyvaso
Revenues, cost of revenues and gross profit
Revenues										325,614	240,382	151,797
Cost of revenues										53,825	31,934	30,131
Gross profit										271,789	208,448	121,666
Adcirca
Revenues, cost of revenues and gross profit
Revenues										122,540	70,580	36,307
Cost of revenues										7,854	4,641	2,428
Gross profit										$ 114,686	$ 65,939	$ 33,879